NCT04611139View on ClinicalTrials.gov

Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

June 30, 2024

Conditions
SCCOHTOvarian Clear Cell TumorOvarian Endometrioid AdenocarcinomaEndometrial Cancer
Interventions
DRUG

SP-2577

Daily oral doses

DRUG

Pembrolizumab

200mg Q3W by IV infusion

Trial Locations (1)

85258

HonorHealth Research Institute, Scottsdale

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Salarius Pharmaceuticals, LLC

INDUSTRY

lead

HonorHealth Research Institute

OTHER